Lialda® with Multi Matrix System Technology (MMX®) goes beyond symptom control to induce complete remission, a stringent treatment standard comprised of both clinical and endoscopic remission.

**Clinical Criteria:**
- No rectal bleeding
- No excessive stool frequency
- Physician’s Global Assessment score ≤1

**Endoscopic Criteria:**
- No friability (no bleeding upon contact)
- Sigmoidoscopic (mucosal) appearance must have improved

Lialda tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of Lialda beyond 8 weeks have not been established.

Lialda is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of Lialda. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (3% of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution should be exercised, and Lialda should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

Lialda tablets are generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (N=625), the most common treatment-related adverse events with Lialda 2.4g/day, 4.8g/day and placebo were headache (5.6%, 3.4% and 0.6%, respectively) and flatulence (4%, 2.8% and 2.8%, respectively). Pancreatitis occurred in less than 1% of patients during clinical trials and resulted in discontinuation of therapy with Lialda.

Lialda® is a registered trademark of Shire LLC.

MMX® is a registered trademark owned by Cosmo Technologies Ltd., Ireland, a wholly-owned subsidiary of Cosmo Pharmaceuticals SpA.

© 2008 Shire US Inc., Wayne, PA 19087
BRIEF SUMMARY: Consult the Full Prescribing Information for complete product information.

**LIALDA™ (mesalamine) Delayed Release Tablets Rx only**

**INDICATIONS AND USAGE**

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond 8 weeks has not been established.

**CONTRAINDICATIONS**

LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA.

**PRECAUTIONS**

General: Patients with pyloric stenosis may have prolonged gastric retention of LIALDA, which could delay mesalamine release in the colon.

The majority of patients who are intolerant or hypersensitive to sulfasalazine can take mesalamine medications without risk of similar reactions. However, caution should be exercised when switching to sulfasalazine in patients with a history of intolerance to sulfasalazine.

Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and rash. If acute intolerance syndrome is suspected, prompt withdrawal is required.

Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported with other mesalamine medications. Caution should be taken in prescribing this medication to patients with conditions predisposing to the development of myocarditis or pericarditis.

Renal: Reports of renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis have been associated with mesalamine medications and pro-drugs of mesalamine. For any patient with known renal dysfunction, caution should be exercised and LIALDA should be used only if the benefits outweigh the risks. It is recommended that all patients have an evaluation of renal function prior to initiation of therapy and periodically while on treatment.

In animal studies with mesalamine, a 13-week oral toxicity study in mice and 13-week and 52-week oral toxicity studies in rats and cynomolgus monkeys have shown the kidney to be the major target organ of mesalamine toxicity. Oral daily doses of 2400 mg/kg in mice and 1150 mg/kg in rats produced renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, renal tubule, papillary necrosis, tubular necrosis, and interstitial nephritis. In cynomolgus monkeys, oral daily doses of 250 mg/kg produced no apparent renal lesions, but there were increased incidences of tubular dilation.

Hepatic Impairment: No information is available on patients with hepatic impairment, and therefore, caution is recommended in these patients.

Infants and Pediatric Patients: Patients should be cautioned to swallow LIALDA tablets whole, taking care not to break the outer coating. The outer coating is designed to remain intact to protect the active ingredient, mesalamine, and ensure its availability throughout the colon.

Drug Interactions: No investigations have been performed between LIALDA and other drugs. However, the following are reported interactions between mesalamine medications and other drugs.

The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of renal reactions. In patients receiving azathioprine or 6-mercaptopurine, concurrent use of mesalamine can increase the risk of potential for blood disorders.

Carcinogenesis, Mutagenesis, Impairment of Fertility: In a 104-week dietary carcinogenicity study in CD-1 mice, mesalamine at doses up to 2000 mg/kg/day was not tumorigenic. This dose is 8 times the maximum recommended human dose (based on a body surface area comparison) of LIALDA. Furthermore, in a 104-week dietary carcinogenicity study in Sprague-Dawley rats, mesalamine at a dose of 800 mg/kg/day was not tumorigenic. This dose is 1.2 times the maximum human dose (based on a body surface area comparison) of LIALDA.

There is no evidence of mutagenicity was observed in an in vitro Ames test or an in vivo mouse micronucleus test.

No effects on fertility or reproductive performance were observed in male or female rats at oral doses of mesalamine up to 400 mg/kg/day (0.7 times the maximum recommended human dose based on a body surface area comparison). Sex abnormalities and intersex in men, which have been reported in association with sulfasalazine, have not been seen with mesalamine products during controlled clinical trials.

Pregnancy: Teratogenic Effects: Pregnancy Category B

Reproduction studies with mesalamine have been performed in rats at doses up to 1000 mg/kg/day (1.8 times the maximum recommended human dose based on a body surface area comparison) and rabbits at doses up to 800 mg/kg/day (2.9 times the maximum recommended human dose based on a body surface area comparison) and have revealed no evidence of impaired fertility or harm to the fetus due to mesalamine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: Low concentrations of mesalamine and higher concentrations of its N-Acetyl metabolite have been detected in human breast milk. While there is limited experience of lactating women using mesalamine, caution should be exercised if LIALDA is administered to a nursing mother, especially in the first 1-2 weeks following birth, if the benefits outweigh the risks.

Pediatric Use: Safety and effectiveness of LIALDA tablets in pediatric patients who are less than 18 years of age have not been studied.

**ADVERSE REACTIONS**

LIALDA tablets have been evaluated in 655 ulcerative colitis patients in controlled and open-label trials.

In two 8-week placebo-controlled clinical trials involving 355 ulcerative colitis patients, 356 received 2.4g/day or 4.8g/day LIALDA tablets and 179 received placebo. More treatment emergent adverse events occurred in the placebo group (119) than in each of the LIALDA treatment groups (109 in 2.4g/day, 92 in 4.8g/day). A lower percentage of LIALDA patients discontinued therapy due to adverse events compared to placebo (2.2% vs 7.3%). The most frequent adverse event leading to discontinuation from LIALDA therapy was exacerbation of ulcerative colitis (0.8%).

The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. The percentage of patients with severe adverse events was higher in the placebo group (6.1% in placebo, 1.1% in 2.4g/day, 2.2% in 4.8g/day). The most common severe adverse events were gastrointestinal disorders which were mainly symptoms associated with ulcerative colitis. Panamnitis occurred in less than 1% of patients during clinical trials and resulted in discontinuation of therapy with LIALDA in patients experiencing this event.

Overall, the percentage of patients who experienced any adverse event was similar across treatment groups. Treatment-related adverse events occurring in LIALDA or placebo groups at a frequency of at least 1% in two Phase 3, 8-week, double blind, placebo-controlled trials are listed in Table 3. The most common treatment-related adverse events with LIALDA 7.4g/day and 4.8g/day were headache (5.6% and 3.4%, respectively) and flatulence (4% and 2.8%, respectively).

<table>
<thead>
<tr>
<th>Event</th>
<th>LIALDA 2.4g/day (n = 177)</th>
<th>LIALDA 4.8g/day (n = 179)</th>
<th>Placebo (n = 179)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>10 (5.6%)</td>
<td>6 (3.4%)</td>
<td>5 (2.9%)</td>
</tr>
<tr>
<td>Flatulence</td>
<td>7 (4%)</td>
<td>5 (2.8%)</td>
<td>5 (2.8%)</td>
</tr>
<tr>
<td>Increased liver enzyme</td>
<td>1 (0.6%)</td>
<td>2 (1.1%)</td>
<td>1 (0.6%)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>0</td>
<td>2 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td>Pruritis</td>
<td>2 (1.2%)</td>
<td>2 (1.1%)</td>
<td>0</td>
</tr>
</tbody>
</table>

The following treatment-related adverse events, presented by body system, were reported infrequently (less than 1%) by LIALDA-treated ulcerative colitis patients in controlled trials.

Cardiovascular and Vascular: tachycardia, hypertension

Dermatological: acne, prurigo, rash, urticaria

Gastrointestinal Disorders: abdominal distention, diarrhea, pancreatitis, rectal polyp, vomiting

Hematological: decreased platelet count

Hepatobiliary Disorders: elevated total bilirubin

Musculoskeletal and Connective Tissue Disorders: arthralgia, back pain

Nervous System Disorders: dizziness, tremor

Respiratory, Thoracic and Mediastinal Disorders: pharyngolaryngitis

General Disorders and Administerative Site Disorders: atrophia, face edema, fatigue, pyrexia

Special Senses: ear pain

**DRUG ABUSE AND DEPENDENCE**

Abuse: None reported.

Dependence: Drug dependence has not been reported with chronic administration of mesalamine.

**OVERDOSAGE**

There have been no reports of overdosage with LIALDA. LIALDA is an anti-inflammatory and symptoms of salicylate toxicity may include tinnitus, vertigo, headache, confusion, drowsiness, sweating, hyperventilation, vomiting, and diarrhea. Severe intoxication may lead to disruption of electrolyte balance and blood pH, hypothermia, and death.

Although there has been no direct experience with LIALDA, conventional therapy for salicylate toxicity may be beneficial in the event of acute overdose. This includes prevention of further gastrointestinal tract absorption by emesis and, if necessary, by gastric lavage. Fluid and electrolyte imbalance should be corrected by the administration of appropriate intravenous therapy. Adequate renal function should be maintained.

**DOSAGE AND ADMINISTRATION**

The recommended dosage for the induction of remission in adult patients, mild to moderate ulcerative colitis is two to four 1.2g tablets to be taken once daily with meals for a total daily dose of 2.4g to 4.8g for eight weeks.

Store at room temperature 15˚C to 25˚C (59˚F to 77˚F); excursions permitted to 30˚C (86˚F). See USP Controlled Room Temperature.


N7600A  Rev. 1/07 GIBFS6